Page 29 - Confidence Interval News Today

Photocure ASA, The Bladder Cancer Company, announces the publication of the study "The Impact of Blue Light Cystoscopy Use Among Non-Muscle Invasive Bladder Cancer Patients in an Equal... | May 4, 2023

1. In this randomized controlled trial, prophylactic administration of tranexamic acid during cesarean section did not lead to a lower risk of composite maternal death or blood transfusion as compared to placebo. 2. There was no difference in the need for surgical or radiologic intervention by seven days postpartum between the treatment and placebo groups.

1. In this randomized controlled trial, bempedoic acid significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with increased cardiovascular risk as compared to placebo. 2. Adverse events that elevated in the bempedoic group included a reduction in renal tubular excretion of uric acid and creatinine as well as incidences of elevated hepatic-enzyme levels and gout.

1. Among patients on stable therapy for pulmonary arterial hypertension (PAH), sotatercept resulted in a significant improvement in six-minute walk distance compared to placebo. 2. Sotatercept was associated with more frequent adverse events, but the benefit-risk ratio was considered favorable and consistent with previous evidence. Evidence Rating Level: 1 (Excellent) Study Rundown: PAH is a

1. In this randomized controlled trial, donor sex did not result in a significant difference in mortality amongst patients receiving red blood cell transfusions. 2. The female-sex donor group was associated with an increased risk of infection in receivers compared to those who received red blood cell transfusions from the male donor group. Evidence Rating

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that XTANDI®...

Until no child has AIDS.

1. In asymptomatic patients, subclinical coronary atherosclerosis was associated with an eight-fold elevated risk for myocardial infarction (MI). 2. Patients with obstructive and extensive subclinical coronary atherosclerosis had the highest risk of MI. Evidence Rating Level: 1 (Excellent) Study Rundown: Subclinical coronary atherosclerosis can precede ischemic heart disease and evolve at an early age, many years before

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023

News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com ... | April 21, 2023